EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Matrixed CDR grafting: A neoclassical framework for antibody humanization and developability

Pankaj Gupta, Alexander M Horspool, Goral Trivedi, Gina Moretti, Akshita Datar, Zhong-Fu Huang, Jeffrey Chiecko, Cynthia Hess Kenny, Michael S Marlow

Journal of Biological Chemistry · 2024

DOI: 10.1016/j.jbc.2023.105555 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2024. Verfasst von Pankaj Gupta und 8 weiteren Autor:innen. Beteiligte Einrichtung: Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA. Electronic address: pankaj.gupta@boehringer-ingelh…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Discovery and optimization of a biotherapeutic monoclonal antibody requires a careful balance of target engagement and physicochemical developability properties. To take full advantage of the sequence diversity provided by different antibody discovery platforms, a rapid and reliable process for humanization of antibodies from nonhuman sources is required. Canonically, maximizing homology of the human variable region (V-region) to the original germline was believed to result in preservation of binding, often without much consideration for inherent molecular properties. We expand on this approach by grafting the complementary determining regions (CDRs) of a mouse anti-LAG3 antibody into an extensive matrix of human variable heavy chain (VH) and variable light chain (VL) framework regions with substantially broader sequence homology to assess the impact on complementary determining region-framework compatibility through progressive evaluation of expression, affinity, biophysical developability, and function. Specific VH and VL framework sequences were associated with major expression and purification phenotypes. Greater VL sequence conservation was correlated with retained or improved affinity. Analysis of grafts that bound the target demonstrated that initial developability criteria were significantly impacted by VH, but not VL. In contrast, cell binding and functional characteristics were significantly impacted by VL, but not VH. Principal component analysis of all factors identified multiple grafts that exhibited more favorable antibody properties, notably with nonoptimal sequence conservation. Overall, this study demonstrates that modern throughput systems enable a more thorough, customizable, and systematic analysis of graft-framework combinations, resulting in humanized antibodies with improved global properties that may progress through development more quickly and with a greater probability of success.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAnimalsHumansMiceAntibody AffinityComplementarity Determining RegionsLymphocyte Activation Gene 3 Protein

Stichwörter der Autor:innen

CDR graftingbiophysical assessmentdevelopabilitygermlineshumanization

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedComplementarity Determining RegionsLag3 protein, humanLymphocyte Activation Gene 3 Protein

Autor:innen und Institutionen

  • Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA. Electronic address: pankaj.gupta@boehringer-ingelheim.com.
  • Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA.
  • Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA. Electronic address: michael.marlow@boehringer-ingelheim.com.

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Gupta, P., Horspool, A. M., Trivedi, G., Moretti, G., Datar, A., Huang, Z. F., Chiecko, J., Kenny, C. H., & Marlow, M. S. (2024). Matrixed CDR grafting: A neoclassical framework for antibody humanization and developability. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2023.105555

Vancouver

Gupta P, Horspool AM, Trivedi G, Moretti G, Datar A, Huang ZF, et al. Matrixed CDR grafting: A neoclassical framework for antibody humanization and developability. Journal of Biological Chemistry. 2024. doi:10.1016/j.jbc.2023.105555

BibTeX
@article{Gupta2024,
  author = {Gupta, Pankaj and Horspool, Alexander M and Trivedi, Goral and Moretti, Gina and Datar, Akshita and Huang, Zhong-Fu and Chiecko, Jeffrey and Kenny, Cynthia Hess and Marlow, Michael S},
  title = {Matrixed CDR grafting: A neoclassical framework for antibody humanization and developability},
  journal = {Journal of Biological Chemistry},
  year = {2024},
  doi = {10.1016/j.jbc.2023.105555}
}
Kostenlos starten →